Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Treatment of chronic hepatitis C in sickle cell disease and thalassaemic patients with interferon and ribavirin.

European journal of gastroenterology & hepatology - 1 Jul 2009

Ancel David, Amiot Xavier, Chaslin-Ferbus Dominique, Hagege Isabelle, Garioud Armand, Girot Robert, Pol Stanislas, Grange Jean-Didier

Abstract excerpt

BACKGROUND/AIM: Hepatic complications are a major cause of death in patients with congenital anaemia and chronic hepatitis C. Ribavirin is usually contraindicated in patients with haemolytic anaemia. This pilot study evaluated the efficacy and safety of antiviral treatment in patients with sickle...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anemia, Hemolytic
Share to Anemia, Sickle Cell
Share to beta-Thalassemia

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Therapy, Combination

Share to Hepatitis C, Chronic

Share to Interferons

Share to Pilot Projects

Share to Ribavirin

Source

Identifiers

PMID: 19404206
DOI: 10.1097/MEG.0b013e3283097699

Genes

SCD

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-19404206-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Treatment of chronic hepatitis C in sickle cell disease and thalassaemic patients with interferon and ribavirin.PMID 19404206Read ↗

Peg-interfon alpha-2a and low-dose ribavirin for treatment of hepatitis C virus infection in patients with sickle-cell anemia in Saudi Arabia.Semantic proximity Read ↗

HCV in sickle cell disease.Semantic proximity Read ↗

The effectiveness of sofosbuvir and daclatasvir in the treatment of hepatitis C in thalassaemia major patients and their effect on haematological factors.Semantic proximity Read ↗

Effectiveness And Safety Of Direct Acting Antiviral Agents In Thalassaemic Patients With Chronic Hepatitis C.Semantic proximity Read ↗

Randomised clinical trial: sofosbuvir and ledipasvir in patients with transfusion-dependent thalassaemia and HCV genotype 1 or 4 infection.Semantic proximity Read ↗

Sofosbuvir/Ledipasvir for Treatment of Chronic Hepatitis C Infection in Adult Patients with β- Thalassemia Major: A Real-Life Study.Semantic proximity Read ↗

Efficacy and safety of interferon-based therapy in the treatment of adult thalassemic patients with chronic hepatitis C: a 12 years audit.Semantic proximity Read ↗

Treatment of chronic hepatitis C in polytransfused thalassaemic patients: a meta-analysis.Semantic proximity Read ↗

Hepatitis C virus infection in a Brazilian population with sickle-cell anemia.Semantic proximity Read ↗

Efficacy of Interferon A-2b monotherapy in Β-thalassemics with chronic hepatitis C.Semantic proximity Read ↗

Factors influencing ribavirin-induced hemolysis.Semantic proximity Read ↗

Ribavirin: current role in the optimal clinical management of chronic hepatitis C.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.